Literature DB >> 11139802

Anticoagulation and heart failure.

S P Graham1.   

Abstract

There are no clear data regarding whether to use warfarin, aspirin, or no therapy in patients with left ventricular systolic dysfunction. Aspirin use is widespread in patients with vascular disease but it can decrease renal blood flow in low output states. Warfarin may be used in patients with advancing heart failure due to the perceived risk of in situ thromboembolism. However, we know that ejection fraction and symptom class do not always match and that the regulation of warfarin dosing is more difficult in worsening heart failure. Drug use must be individualized, based on knowledge of underlying heart failure etiology, functional class, drug side effects, and renal function. We await ongoing studies to elucidate the differential effects of these drugs on global outcome as well as on the mechanisms by which they achieve their results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139802     DOI: 10.1007/s11886-001-0013-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  31 in total

1.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.

Authors:  S MacMahon; N Sharpe; G Gamble; A Clague; C N Mhurchu; T Clark; H Hart; J Scott; H White
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Differential inhibition of prostacyclin production and platelet aggregation by aspirin.

Authors:  G Masotti; G Galanti; L Poggesi; R Abbate; G G Neri Serneri
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

4.  Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.

Authors:  A S Al-Khadra; D N Salem; W M Rand; J E Udelson; J J Smith; M A Konstam
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

5.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.

Authors:  C S Landefeld; L Goldman
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

6.  Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease.

Authors:  J Leor; H Reicher-Reiss; U Goldbourt; V Boyko; S Gottlieb; A Battler; S Behar
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

7.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors: 
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

8.  Risk factors for intracranial hemorrhage in outpatients taking warfarin.

Authors:  E M Hylek; D E Singer
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

9.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

10.  Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.

Authors:  D Hall; H Zeitler; W Rudolph
Journal:  J Am Coll Cardiol       Date:  1992-12       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.